These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38091571)

  • 1. Haloperidol's introduction in the United States: A tale of a failed trial and its consequences.
    Tavares J
    J Hist Neurosci; 2024; 33(2):169-179. PubMed ID: 38091571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The haloperidol story.
    Granger B; Albu S
    Ann Clin Psychiatry; 2005; 17(3):137-40. PubMed ID: 16433054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice.
    López-Muñoz F; Alamo C
    Brain Res Bull; 2009 Apr; 79(2):130-41. PubMed ID: 19186209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of the clinical effects of timiperone, a new butyrophenone derivative, and haloperidol on schizophrenia using a double-blind technique.
    Kariya T; Shimazono Y; Itoh H; Mori A; Murasaki M; Sugano K; Toru M; Yamashita I
    J Int Med Res; 1983; 11(2):66-77. PubMed ID: 6133803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haloperidol: a quarter century of experience.
    Settle EC; Ayd FJ
    J Clin Psychiatry; 1983 Dec; 44(12):440-8. PubMed ID: 6418723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [CLINICAL TRIAL OF A NEW NEUROLEPTIC IN LABOR. 4-(4-HYDROXY-4-PHENYL-PIPERIDINE)-BUTYROPHENONE].
    ARDILLO L; MAINARDI C
    Minerva Ginecol; 1965 Jan; 17():133-6. PubMed ID: 14299812
    [No Abstract]   [Full Text] [Related]  

  • 7. [Clinical trials of a new neuroleptic of the butyrophenone group].
    VELLOSO FM; PAPROCKI J
    Hospital (Rio J); 1963 Jun; 63():1427-34. PubMed ID: 13996630
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravenous haloperidol for tranquilization in critical care patients: a review and critique.
    Ziehm SR
    AACN Clin Issues Crit Care Nurs; 1991 Nov; 2(4):765-77. PubMed ID: 1954061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classics in Chemical Neuroscience: Haloperidol.
    Tyler MW; Zaldivar-Diez J; Haggarty SJ
    ACS Chem Neurosci; 2017 Mar; 8(3):444-453. PubMed ID: 28170220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [THE USE OF A BUTYROPHENONE NEUROLEPTIC (HALOPERIDOL) IN ACUTE AND CHRONIC PSYCHOSES].
    MADALENA JC; FERREIRA LR; BELLO H
    Rev Assoc Med Bras; 1963; 9():375-86. PubMed ID: 14163287
    [No Abstract]   [Full Text] [Related]  

  • 11. Neuroleptics in the treatment of aggressive challenging behaviour for people with intellectual disabilities: a randomised controlled trial (NACHBID).
    Tyrer P; Oliver-Africano P; Romeo R; Knapp M; Dickens S; Bouras N; Ahmed Z; Cooray S; Deb S; Murphy D; Hare M; Meade M; Reece B; Kramo K; Bhaumik S; Harley D; Regan A; Thomas D; Rao B; Karatela S; Lenôtre L; Watson J; Soni A; Crawford M; Eliahoo J; North B
    Health Technol Assess; 2009 Apr; 13(21):iii-iv, ix-xi, 1-54. PubMed ID: 19397849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Psycho-pharmacological study of a 5th butyrophenone: "methylperidide", a neuroleptic pyrrolidinamide and methyl derivative of haloperidol].
    DIVRY P; BOBON J; COLLARD J; DEMARET A
    Acta Neurol Psychiatr Belg; 1960 Dec; 60():1073-86. PubMed ID: 13723131
    [No Abstract]   [Full Text] [Related]  

  • 13. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
    Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
    Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The discovery of haloperidol].
    Granger B
    Encephale; 1999; 25(1):59-66. PubMed ID: 10205735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forty years of antipsychotic Drug research--from haloperidol to paliperidone--with Dr. Paul Janssen.
    Awouters FH; Lewi PJ
    Arzneimittelforschung; 2007; 57(10):625-32. PubMed ID: 18074755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders.
    Dold M; Samara MT; Li C; Tardy M; Leucht S
    Cochrane Database Syst Rev; 2015 Jan; 1(1):CD009831. PubMed ID: 25592299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).
    Powney MJ; Adams CE; Jones H
    Cochrane Database Syst Rev; 2012 Nov; 11():CD009377. PubMed ID: 23152276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind study with two butyrophenone derivatives: bromperidol vs. haloperidol.
    Pöldinger W; Bures E; Haage H
    Int Pharmacopsychiatry; 1977; 12(3):184-92. PubMed ID: 334688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of haloperidol and penfluridol in pregnancy: a multicenter, prospective, controlled study.
    Diav-Citrin O; Shechtman S; Ornoy S; Arnon J; Schaefer C; Garbis H; Clementi M; Ornoy A
    J Clin Psychiatry; 2005 Mar; 66(3):317-22. PubMed ID: 15766297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation).
    Ostinelli EG; Brooke-Powney MJ; Li X; Adams CE
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD009377. PubMed ID: 28758203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.